Yuji Sakuma

Dr. Yuji Sakuma

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 July 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MYMiki Yamaguchi
Miki Yamaguchi
SHSachie Hirai
Sachie Hirai
YTYusuke Tanaka
Yusuke Tanaka
TSToshiyuki Sumi
Toshiyuki Sumi
MTMakoto Tada
Makoto Tada
YSYuji Sakuma
Yuji Sakuma

2 April 2015 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
RHRurika Hamanaka
Rurika Hamanaka
TYTomoyuki Yokose
Tomoyuki Yokose
YSYuji Sakuma
Yuji Sakuma
MTMasahiro Tsuboi
Masahiro Tsuboi
HIHiroyuki Ito
Hiroyuki Ito
MIMasayuki Iwazaki
Masayuki Iwazaki
Patients with pathologic stage (p-Stage) IA non-small cell lung cancer (NSCLC) have a good survival rate because of possible curative resection. However, up to 10% of these patients relapse postoperatively. To identify unfavorable prognostic factors, we retrospectively analyzed the clinicopathological features of p-Stage IA disease, focusing on vascular invasion. Of 467 patients with p-Stage I NSCLC, 335 were diagnosed with p-Stage IA or IB disease based on a lesion size ≤3 cm and the presence of pleural invasion (PL). Univariate and multivariate analyses of recurrence-free survival (RFS) were performed with age, sex, PL, and vascular invasion (blood vessel invasion [v] and lymphatic vessel invasion [ly]) as variables. To examine vascular invasion, hematoxylin-eosin (HE), Elastica van Gieson staining, and immunostaining with anti-podoplanin antibody were performed. The presence or absence of v and ly was recorded; the number of involved vessels was counted. Survival rates were obtained using the Kaplan–Meier method and log-rank test. Multivariate analyses were performed using the Cox proportional hazards model. RFS differed significantly between patients with no or one involved blood vessel (0 v or 1 v) and those with ≥2 involved vessels (≥2 v). Similarly, RFS differed significantly between patients with no lymphatic vessel involvement (0 ly) and those with one involved lymphatic vessel (1 ly). Thus, BVI(+) and BVI(−) were defined as ≥2 v and 0 v + 1 v, and LVI(+) and LVI(−) as ≥1 ly and 0 ly, respectively. BVI and LVI together represented tumor vessel invasion (TVI). On multivariate analyses, PL and TVI were independently associated with recurrence. Additionally, patients with p-Stage IA TVI(+) disease had a comparable recurrence rate to those with p-Stage IB disease. Similar to PL, TVI is an important factor increasing the likelihood of recurrence. As HE staining alone is insufficient for evaluating vascular invasion, specific staining is necessary. Moreover, patients with p-Stage IA TVI(+) disease had a recurrence rate comparable to those with p-Stage IB disease; therefore, further studies should aim to elucidate whether patients with p-Stage IA TVI(+) disease should be administered postoperative chemotherapy similar to that received by p-Stage IB patients. The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5213064891369688

1 November 2018 in Experimental Cell Research
Verified
Journal Article
Closed access
YTYusuke Tanaka
Yusuke Tanaka
MYMiki Yamaguchi
Miki Yamaguchi
SHSachie Hirai
Sachie Hirai
TSToshiyuki Sumi
Toshiyuki Sumi
MTMakoto Tada
Makoto Tada
YSYuji Sakuma
Yuji Sakuma

1 April 2016 in Laboratory Investigation
Verified
Journal Article
Open access
PDF file
YSYuji Sakuma
Yuji Sakuma
HNHirotaka Nishikiori
Hirotaka Nishikiori
SHSachie Hirai
Sachie Hirai
MYMiki Yamaguchi
Miki Yamaguchi
GYGen Yamada
Gen Yamada
HTHiroki Takahashi
Hiroki Takahashi
The secondary epidermal growth factor receptor (EGFR) T790M mutation is the most prominent mechanism that confers resistance to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs) in lung cancer treatment. Although third-generation EGFR TKIs can suppress the kinase activity of T790M-positive EGFR, they still cannot eradicate EGFR-mutated cancer cells. We previously reported that a subpopulation of EGFR-mutant lung adenocarcinomas depends on enhanced autophagy, instead of EGFR, for survival, and in this study we explore another mechanism that contributes to TKI resistance. We demonstrate here that an EGFR-mutant lung adenocarcinoma cell line, H1975 (L858R+T790M), has a subset of cells that exhibits an epithelial–mesenchymal transition (EMT) phenotype and can thrive in the presence of third-generation EGFR TKIs. These cells depend on not only autophagy but also on the isomerase Pin1 for survival in vitro, unlike their parental cells. The Pin1 protein was expressed in an EGFR-mutant lung cancer tissue that has undergone partial EMT and acquired resistance to EGFR TKIs, but not its primary tumor. These findings suggest that inhibition of Pin1 activity can be a novel strategy in lung cancer treatment.

1 June 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MYMiki Yamaguchi
Miki Yamaguchi
SHSachie Hirai
Sachie Hirai
TSToshiyuki Sumi
Toshiyuki Sumi
YTYusuke Tanaka
Yusuke Tanaka
MTMakoto Tada
Makoto Tada
YSYuji Sakuma
Yuji Sakuma